Biotech organic social lives or dies on LinkedIn, and it routes through the same regulatory review built for clinical claims – even for a conference recap. Most companies respond by posting nothing, or posting so little that legal never has to weigh in. We build the content pipeline and the review lane that let your scientific and executive team post consistently without waiting three weeks for sign-off.
The Problem
Every post routes through the review process built for clinical claims
A conference recap, a hiring announcement, and a data readout should not clear the same compliance bar, but at most biotech companies they do, because no one has separated low-risk corporate content from anything data-adjacent. The result is a review queue where a photo from BIO sits next to a statement about trial enrollment, and both wait the same three weeks. Posting cadence collapses to almost nothing, or the team gives up and stops asking.
Your scientific leaders are the best distribution channel and the least equipped to use it
CSOs, CMOs, and principal investigators carry the credibility that actually moves KOL and investor attention on LinkedIn – far more than a corporate account ever will. But they are scientists, not content creators, and no one has built them a repeatable way to turn a conference talk, a published paper, or a hallway conversation into something postable. Their expertise sits in their heads and never reaches the feed.
Patient-facing organic social carries real exposure most teams do not weigh correctly
Organic social for a company below Phase III or commercial stage has a narrow legitimate lane, and it is corporate, investor, and talent-facing content – not patient-facing content, which carries regulatory exposure most legal teams will not clear pre-commercial. Teams that do not understand this either avoid social entirely out of caution, wasting the reach they do have, or post patient-adjacent content that should never have gotten past review in the first place.
KOL amplification happens by accident, not by design
When a KOL mentions your data, shares a booth photo, or tags your account after a conference, that moment is worth more than almost anything your own account can post – and most biotech teams have no process to notice it, request a compliant reshare, or follow up. The mention gets a like from the marketing intern and disappears. Nobody owns turning earned attention into extended reach.
How We Help
Our assessment starts by auditing who is actually posting today, what gets approved versus stuck in review, and how long that review takes end to end. We categorize the last six months of attempted content into what should have been a fast approval and what genuinely needed full medical, legal, and regulatory sign-off. Most companies discover the bottleneck is process, not content – three or four people touch every post regardless of risk level.
Strategy development builds two things: a set of content pillars scoped to what is legitimately postable at your stage – platform and pipeline explainers, conference presence, hiring and culture, investor-facing milestones, KOL and publication amplification – and a two-lane review process that routes low-risk corporate content through a fast approval while anything data-adjacent still gets full regulatory review. This is the single change that unlocks posting cadence without touching your compliance standards.
Execution starts with your executives and scientific leads, not a brand account. We run a structured interview and ghostwriting process that turns what your CSO or CMO already says in meetings and at conferences into LinkedIn posts they can review and approve in minutes, not draft from scratch. We build pre-cleared post templates for recurring moments – conference attendance, publication announcements, hiring milestones – so the fast lane has real content ready to move through it.
For KOL amplification, we build a lightweight monitoring and outreach process: when a KOL or investor mentions your company, data, or team, someone owns following up, requesting a compliant reshare where appropriate, and thanking the person directly. This alone extends reach further than most in-house content calendars, because it borrows credibility your own account cannot manufacture.
Measurement tracks engagement from the audiences who actually matter for biotech – investor and analyst engagement on milestone posts, recruiting inquiries generated by hiring and culture content, and KOL or publication mentions your team amplified. Follower count is close to meaningless in this vertical; a post seen by forty of the right analysts outperforms one seen by four thousand strangers.
What we deliver
- Content review audit – separating fast-lane corporate content from full-review clinical or data-adjacent content
- Executive and scientific leadership ghostwriting system – turning real work into postable content in a compliant format
- Pre-cleared post templates for recurring moments – conferences, publications, hiring, investor milestones
- KOL and mention monitoring process – a system for noticing and extending earned amplification, not catching it by accident
The bottleneck on biotech organic social is almost never the content – it's a review process built for clinical claims being applied to a hiring post. Fix the lane, not the caption, and posting cadence changes overnight.
Our Methodology
Our organic social build for biotech and pharma runs as a 90-day installation, starting with process before content. Phase one audits your current posting activity, review timeline, and who actually holds sign-off across marketing, legal, medical affairs, and regulatory – most companies have never mapped this end to end and are surprised by how many hands touch a routine post.
Phase two designs the two-lane review process and the content pillars scoped to your stage, then runs the first ghostwriting interviews with your executive and scientific leads. We draft and clear a batch of pre-cleared templates for recurring moments, so the fast lane has real inventory from week one instead of an empty content calendar.
Phase three runs the system: regular ghostwriting sessions with leadership, KOL monitoring and outreach, and a posting cadence your team can sustain once we hand it off. Unlike a social media agency that manages a brand account in isolation, we build the review infrastructure first, because in biotech and pharma the process is what determines whether anything gets posted at all.
How We Work
Initial engagements run 3-4 months. The first 30 days are the review audit and process redesign – we interview your legal, medical affairs, and regulatory stakeholders to map the real approval bottleneck and get sign-off on the two-lane process before we write a single post. Days 31-60 build the content pillars, run the first ghostwriting sessions with your executive and scientific leads, and clear the initial batch of pre-cleared templates. Days 61-90 run the system at posting cadence and stand up the KOL monitoring process.
Our team includes a content strategist who owns the pillars and calendar, a ghostwriter who runs the executive interview and drafting process, and an account lead who manages the two-lane review relationship with your legal and regulatory reviewers. From your side we need 30-45 minutes a month from each executive or scientific lead we are ghostwriting for, and a named reviewer for the fast lane.
Cadence settles into biweekly ghostwriting sessions with leadership, a standing content calendar reviewed monthly, and ongoing KOL monitoring handled on our side with a weekly digest to your team. Most companies see posting frequency change within the first 60 days, once the two-lane process is actually running instead of theoretical.
Engagements typically extend past the initial 3-4 months because organic social compounds – the value of a consistent executive voice on LinkedIn builds over quarters, not weeks, and the ghostwriting relationship gets faster and more natural the longer it runs.
- Faster review turnaround on low-risk corporate content, without changing compliance standards
- Consistent executive and scientific leadership presence on LinkedIn
- KOL and investor engagement quality on milestone and platform posts
- Recruiting inquiries generated by hiring and culture content
If your biotech & pharma company needs organic social leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does organic social cost for a biotech or pharma company?
Organic social engagements typically run $8K-$20K a month depending on how many executives and scientific leads we are ghostwriting for and how much process redesign the review workflow needs upfront. Companies with an already-functional fast lane for corporate content cost less to onboard than companies where every post still routes through full regulatory review.
How long before we see results from an organic social engagement?
The two-lane review process is usually running within 30-45 days, which is when posting cadence changes most visibly. Executive ghostwriting content typically starts publishing by day 45-60 once the first interviews are done and templates are cleared.
How does the ghostwriting process work with our scientific and executive team?
We run short structured interviews, usually 20-30 minutes, built around what your CSO, CMO, or CEO is already thinking about – a recent conference talk, a paper, a hiring decision. We draft in their voice, they review and edit before anything publishes, and the interview cadence repeats biweekly or monthly depending on how much they want to post. Nothing goes live without their sign-off.
What makes Winston Francois different from a social media agency?
Most social media agencies manage a brand account and post generic content calendars; we start from the compliance bottleneck that actually stops biotech companies from posting at all. We build the two-lane review process alongside legal and regulatory, then ghostwrite for the humans whose credibility actually moves the audiences that matter – investors, KOLs, and talent. The process work is the differentiator, not the caption writing.
How do you measure ROI on organic social for a biotech company?
We track engagement quality from the audiences that matter – investor and analyst interaction on milestone posts, recruiting inquiries tied to hiring and culture content, and instances of KOL or publication amplification our team extended. Follower growth is a weak signal in this vertical. The real measure is whether the right forty people are seeing and responding to what your leadership posts, not whether the account is growing.
Can we run patient-facing content through this service?
For most companies below Phase III or commercial stage, no – patient-facing organic social carries regulatory exposure that legal will not clear, and we will tell you that directly rather than build content you cannot publish. Our focus is corporate, investor, and talent-facing content, which is where the legitimate reach is at earlier stages. Commercial-stage companies with an approved patient-facing program are a separate conversation with different review requirements.
